Good Start for local businesses
Thursday, 22 July, 2004
Life science companies - from start-ups to listed biotechs - featured highly in the latest round of Commonwealth R&D Start funding, it was revealed yesterday.
About a dozen life science-related firms netted more than AUD$15 million of the total pool of $65.15 million awarded between April 2 and June 30.
Among them were listed company Agen Biomedical, a division of listed company Agenix (ASX:AGX), which was awarded more than $1.128 million towards the continued development of its Thromboview blood clot imaging technology.
The biggest grant overall was one of almost $9.4 million to Seeley International, for its integrated climate control system.
Life science grantees included:
- Vaxine (ACT), $764,996 -- Novel, aluminium-free hepatitis B vaccine
- Biosceptre (NSW), $2,091,077 -- Broad-spectrum anti-cancer topical cream
- Zestwin (NSW), $175,000 --- Non-toxic chemical coating for sheep
- CathRX (NSW) with University of Western Sydney, $1,496,593 -- Sensing and ablation range for abnormal heart rhythms
- Agen Biomedical (Qld), $1.128,758 -- ThromboView
- Glycoz (Qld), $1,838,000 -- New carbohydrate-based antibiotic
- Genetraks (Qld), $1,015,816 -- Gene-based diagnostic test for EPM
- Hexima (Vic), $656,197 -- Insect-resistant technology in cotton
- Ultimate Medical (Vic), $264,783 -- Novel single-use medical airway device
- GBC Scientific Equipment (Vic), $1,837,555 -- New HPLC instrumentation
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
